SAXAGEN-M 500 SR Tablets

Description

Saxagliptin 

• Drug class: Dipeptidyl peptidase-4 (DPP-4) inhibitors

• Weight neutral with low risk of hypoglycemia.

• Demonstrates a statistically significant and clinically meaningful improvement in glycemic control.

• More efficacious and have a better safety profile than acarbose and sulfonylurea.

• Efficiently lowers FPG (fasting plasma glucose) and PPG (Postprandial glucose levels in combination therapy with metformin.

Metformin

• Drug class: Biguanides 

Metformin HCI

• Excellent hyperglycaemic agent lowers blood sugar levels without causing hypoglycemia.

• Effectual in the treatment of Type 2 diabetes mellitus, Gestational diabetes, and non-insulin-dependent diabetes mellitus in obese patients.

• Its sustained release mechanism reduces adverse effects and improves medication adherence.

• Improves endothelial oxidative stress levels, and insulin sensitivity and attenuates hyperglycemia-induced inflammation.

Saxagliptin (SAXA)/metformin (MET) Fixed-dose combination (FDC) 2.5/500 mg

• SAXA/MET FDC is a patient-friendly, dosage-flexible, and hypoglycemia-safe with very few adverse events and a neutral or even favorable effect on body weight.

• It achieves significant glycosylated hemoglobin A_1c reduction helping the patient to achieve his/her individual glycemic goals.

• SAXA/MET FDC represents a good choice for amplifying patients’ compliance and adherence to the therapeutic regimen.